:Senicapoc
{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 450848962
| ImageFile=Senicapoc.png
| ImageSize=200px
| PIN=2,2-Bis(4-fluorophenyl)-2-phenylacetamide
| OtherNames=
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = TS6G201A6Q
| IUPHAR_ligand = 2331
| CASNo_Ref = {{cascite|correct|??}}
| CASNo=289656-45-7
| PubChem=216327
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06640
| SMILES=C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 187516
| InChI = 1/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)
| InChIKey = SCTZUZTYRMOMKT-UHFFFAOYAR
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = SCTZUZTYRMOMKT-UHFFFAOYSA-N
}}
|Section2={{Chembox Properties
| Formula=C20H15F2NO
| MolarMass=323.34 g/mol
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
}}
|Section3={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
}}
}}
Senicapoc (ICA-17043) is a Gardos channel blocker.{{cite journal |vauthors=Ataga KI, Smith WR, De Castro LM, etal |title=Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia |journal=Blood |volume=111 |issue=8 |pages=3991–7 |date=April 2008 |pmid=18192510 |doi=10.1182/blood-2007-08-110098 |url=http://www.bloodjournal.org/cgi/pmidlookup?view=long&pmid=18192510|doi-access=free }}{{cite journal |vauthors=McNaughton-Smith GA, Burns JF, Stocker JW, etal |title=Novel inhibitors of the Gardos channel for the treatment of sickle cell disease |journal=J. Med. Chem. |volume=51 |issue=4 |pages=976–82 |date=February 2008 |pmid=18232633 |doi=10.1021/jm070663s}}
It has been proposed for use in sickle cell anemia.{{cite journal |author1=Ataga KI |author2=Stocker J |title=Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia |journal=Expert Opin Investig Drugs |volume=18 |issue=2 |pages=231–9 |date=February 2009 |pmid=19236269 |doi=10.1517/13543780802708011 |s2cid=73061898 }} Gardos channel blockers may work in the treatment of sickle cell anemia by blocking the efflux of potassium and water from red blood cells, thereby preventing the dehydration of red blood cells and stopping the polymerization of HbS.
The Gardos channel has been identified as KCNN4.{{cite journal |author1=Hoffman JF |author2=Joiner W |author3=Nehrke K |author4=Potapova O |author5=Foye K |author6=Wickrema A |title=The hSK4 (KCNN4) isoform is the Ca2+-activated K+ channel (Gardos channel) in human red blood cells |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=100 |issue=12 |pages=7366–71 |date=June 2003 |pmid=12773623 |pmc=165881 |doi=10.1073/pnas.1232342100 |bibcode=2003PNAS..100.7366H |doi-access=free }}
The "ICA" is for Icagen, which is developing the drug.{{cite web |url=http://ir.icagen.com/phoenix.zhtml?c=178443&p=irol-newsArticle&ID=1207330&highlight= |title=Icagen - Press Release |format= |accessdate=2008-12-22}}